Nho Shikoku Cancer Center

Matsuyama, Ehime 791-0280

2 studies enrolling now · 15 studies all time

What they study most

Advanced or Metastatic Gastric or Gastroesophageal Cancer, Advanced or Metastatic Solid Tumor, Breast Cancer, CLL, Carcinoma, Non-Small-Cell Lung, Cervical Cancer, Chronic Lymphocytic Leukemia, Colorectal Neoplasms, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Fallopian Tube Cancer, Gastric, or Gastroesophageal Junction Adenocarcinoma

Studies at this site

• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors — Recruiting now
• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) — Recruiting now
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer — Recruiting now
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) — Running, not enrolling
• A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer — Running, not enrolling
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer — Completed
• Futibatinib in Patients With Specific FGFR Aberrations — Stopped early
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
• A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) — Stopped early
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma — Completed
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial — Completed